Need professional-grade analysis? Visit stockanalysis.com
$2.18B
N/A
N/A
N/A
Bavarian Nordic A/S (BVNKF) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $30.73.
Over the past year, BVNKF has traded between a low of $23.07 and a high of $37.60. The stock has gained 33.2% over this period. It is currently 18.3% below its 52-week high.
Bavarian Nordic A/S has a market capitalization of $2.18B.
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Side-by-side comparison against top Healthcare peers.